Ignite Creation Date:
2024-05-05 @ 11:10 PM
Last Modification Date:
2024-10-26 @ 10:29 AM
Study NCT ID:
NCT01263366
Status:
TERMINATED
Last Update Posted:
2013-04-19
First Post:
2010-12-16
Brief Title:
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
Sponsor:
ProCertus BioPharm Inc
Organization:
ProCertus BioPharm Inc
Study Overview
Official Title:
Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
Status:
TERMINATED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Enrollment issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study a nonrandomized open-label Phase I safety and exploratory study will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy
The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients
The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None